Global Opioid-Induced Constipation Market Research Report 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 108

Report ID: 12213

Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
North America is the largest Sales place, with a Sales market share nearly 56.48% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 20.49%.

The global Opioid-Induced Constipation market is valued at 2110 million US$ in 2018 is expected to reach 3060 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2019-2025.
This report focuses on Opioid-Induced Constipation volume and value at global level, regional level and company level. From a global perspective, this report represents overall Opioid-Induced Constipation market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Other

Segment by Application
Hospital
Pharmacy
Other

Table of Contents

Executive Summary
1 Opioid-Induced Constipation Market Overview
1.1 Product Overview and Scope of Opioid-Induced Constipation
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Other
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Opioid-Induced Constipation Consumption Comparison by Application (2014-2025)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market by Region
1.4.1 Global Opioid-Induced Constipation Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global Opioid-Induced Constipation Market Size
1.5.1 Global Opioid-Induced Constipation Revenue (2014-2025)
1.5.2 Global Opioid-Induced Constipation Production (2014-2025)

2 Global Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Production Market Share by Manufacturers (2014-2019)
2.2 Global Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Opioid-Induced Constipation Production Sites, Area Served, Product Types
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate
2.5.2 Opioid-Induced Constipation Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Opioid-Induced Constipation Production Market Share by Regions
3.1 Global Opioid-Induced Constipation Production Market Share by Regions
3.2 Global Opioid-Induced Constipation Revenue Market Share by Regions (2014-2019)
3.3 Global Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Opioid-Induced Constipation Production
3.4.1 North America Opioid-Induced Constipation Production Growth Rate (2014-2019)
3.4.2 North America Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Opioid-Induced Constipation Production
3.5.1 Europe Opioid-Induced Constipation Production Growth Rate (2014-2019)
3.5.2 Europe Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Opioid-Induced Constipation Production (2014-2019)
3.6.1 China Opioid-Induced Constipation Production Growth Rate (2014-2019)
3.6.2 China Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Opioid-Induced Constipation Production (2014-2019)
3.7.1 Japan Opioid-Induced Constipation Production Growth Rate (2014-2019)
3.7.2 Japan Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Opioid-Induced Constipation Consumption by Regions
4.1 Global Opioid-Induced Constipation Consumption by Regions
4.2 North America Opioid-Induced Constipation Consumption (2014-2019)
4.3 Europe Opioid-Induced Constipation Consumption (2014-2019)
4.4 China Opioid-Induced Constipation Consumption (2014-2019)
4.5 Japan Opioid-Induced Constipation Consumption (2014-2019)

5 Global Opioid-Induced Constipation Production, Revenue, Price Trend by Type
5.1 Global Opioid-Induced Constipation Production Market Share by Type (2014-2019)
5.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2014-2019)
5.3 Global Opioid-Induced Constipation Price by Type (2014-2019)
5.4 Global Opioid-Induced Constipation Production Growth by Type (2014-2019)

6 Global Opioid-Induced Constipation Market Analysis by Applications
6.1 Global Opioid-Induced Constipation Consumption Market Share by Application (2014-2019)
6.2 Global Opioid-Induced Constipation Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Opioid-Induced Constipation Business
7.1 Takeda Pharmaceuticals
7.1.1 Takeda Pharmaceuticals Opioid-Induced Constipation Production Sites and Area Served
7.1.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 Bayer
7.2.1 Bayer Opioid-Induced Constipation Production Sites and Area Served
7.2.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.2.3 Bayer Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Sanofi
7.3.1 Sanofi Opioid-Induced Constipation Production Sites and Area Served
7.3.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.3.3 Sanofi Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served
7.4 Mallinckrodt
7.4.1 Mallinckrodt Opioid-Induced Constipation Production Sites and Area Served
7.4.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.4.3 Mallinckrodt Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.4.4 Main Business and Markets Served
7.5 Salix (Bausch Health)
7.5.1 Salix (Bausch Health) Opioid-Induced Constipation Production Sites and Area Served
7.5.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.5.3 Salix (Bausch Health) Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.5.4 Main Business and Markets Served
7.6 AstraZeneca
7.6.1 AstraZeneca Opioid-Induced Constipation Production Sites and Area Served
7.6.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.6.3 AstraZeneca Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.6.4 Main Business and Markets Served
7.7 Progenics Pharmaceuticals
7.7.1 Progenics Pharmaceuticals Opioid-Induced Constipation Production Sites and Area Served
7.7.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.7.4 Main Business and Markets Served
7.8 Purdue Pharm
7.8.1 Purdue Pharm Opioid-Induced Constipation Production Sites and Area Served
7.8.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.8.3 Purdue Pharm Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.8.4 Main Business and Markets Served
7.9 Nektar Therapeutics
7.9.1 Nektar Therapeutics Opioid-Induced Constipation Production Sites and Area Served
7.9.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.9.3 Nektar Therapeutics Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.9.4 Main Business and Markets Served
7.10 Daiichi Sankyo
7.10.1 Daiichi Sankyo Opioid-Induced Constipation Production Sites and Area Served
7.10.2 Opioid-Induced Constipation Product Introduction, Application and Specification
7.10.3 Daiichi Sankyo Opioid-Induced Constipation Production, Revenue, Price and Gross Margin (2014-2019)
7.10.4 Main Business and Markets Served
7.11 Prestige
7.12 GSK
7.13 Shionogi

8 Opioid-Induced Constipation Manufacturing Cost Analysis
8.1 Opioid-Induced Constipation Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Opioid-Induced Constipation
8.4 Opioid-Induced Constipation Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Opioid-Induced Constipation Distributors List
9.3 Opioid-Induced Constipation Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Opioid-Induced Constipation Market Forecast
11.1 Global Opioid-Induced Constipation Production, Revenue Forecast
11.1.1 Global Opioid-Induced Constipation Production Growth Rate Forecast (2019-2025)
11.1.2 Global Opioid-Induced Constipation Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Opioid-Induced Constipation Price and Trend Forecast (2019-2025)
11.2 Global Opioid-Induced Constipation Production Forecast by Regions (2019-2025)
11.2.1 North America Opioid-Induced Constipation Production, Revenue Forecast (2019-2025)
11.2.2 Europe Opioid-Induced Constipation Production, Revenue Forecast (2019-2025)
11.2.3 China Opioid-Induced Constipation Production, Revenue Forecast (2019-2025)
11.2.4 Japan Opioid-Induced Constipation Production, Revenue Forecast (2019-2025)
11.3 Global Opioid-Induced Constipation Consumption Forecast by Regions (2019-2025)
11.3.1 North America Opioid-Induced Constipation Consumption Forecast (2019-2025)
11.3.2 Europe Opioid-Induced Constipation Consumption Forecast (2019-2025)
11.3.3 China Opioid-Induced Constipation Consumption Forecast (2019-2025)
11.3.4 Japan Opioid-Induced Constipation Consumption Forecast (2019-2025)
11.4 Global Opioid-Induced Constipation Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Opioid-Induced Constipation Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer